MX367109B - Composiciones bacterianas sinergicas y sus metodos de produccion y usos. - Google Patents

Composiciones bacterianas sinergicas y sus metodos de produccion y usos.

Info

Publication number
MX367109B
MX367109B MX2016006708A MX2016006708A MX367109B MX 367109 B MX367109 B MX 367109B MX 2016006708 A MX2016006708 A MX 2016006708A MX 2016006708 A MX2016006708 A MX 2016006708A MX 367109 B MX367109 B MX 367109B
Authority
MX
Mexico
Prior art keywords
production
methods
bacterial compositions
synergistic bacterial
synergistic
Prior art date
Application number
MX2016006708A
Other languages
English (en)
Other versions
MX2016006708A (es
Inventor
B Afeyan Noubar
Arthur Berry David
Von Maltzahn Geoffrey
R HENN Matthew
Mario D'onofrio Anthony
Daniel Litcofsky Kevin
K Ohsumi Toshiro
Jane Lombardo Mckenzie Mary-
N Cook David
Grant AUNINS John
Original Assignee
Seres Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Therapeutics Inc filed Critical Seres Therapeutics Inc
Publication of MX2016006708A publication Critical patent/MX2016006708A/es
Publication of MX367109B publication Critical patent/MX367109B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones terapéuticas que contienen poblaciones microbianas para prevención, tratamiento y reducción de los síntomas asociados con una disbiosis de un sujeto mamífero tal como un ser humano.
MX2016006708A 2013-11-25 2014-11-25 Composiciones bacterianas sinergicas y sus metodos de produccion y usos. MX367109B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361908702P 2013-11-25 2013-11-25
US201361908698P 2013-11-25 2013-11-25
US201462004187P 2014-05-28 2014-05-28
PCT/US2014/067491 WO2015077794A1 (en) 2013-11-25 2014-11-25 Synergistic bacterial compositions and methods of production and use thereof

Publications (2)

Publication Number Publication Date
MX2016006708A MX2016006708A (es) 2016-10-26
MX367109B true MX367109B (es) 2019-08-05

Family

ID=52278746

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006708A MX367109B (es) 2013-11-25 2014-11-25 Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2019009132A MX2019009132A (es) 2013-11-25 2016-05-23 Composiciones bacterianas sinergicas y sus metodos de produccion y usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009132A MX2019009132A (es) 2013-11-25 2016-05-23 Composiciones bacterianas sinergicas y sus metodos de produccion y usos.

Country Status (11)

Country Link
US (3) US10258655B2 (es)
EP (1) EP3074027A1 (es)
JP (3) JP6833514B2 (es)
KR (3) KR102379658B1 (es)
CN (2) CN116370507A (es)
AU (3) AU2014352643A1 (es)
BR (1) BR112016011830A2 (es)
CA (2) CA3203756A1 (es)
MX (2) MX367109B (es)
RU (1) RU2722482C2 (es)
WO (1) WO2015077794A1 (es)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2011286165B2 (en) 2010-08-04 2016-10-20 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP3360560A1 (en) 2012-03-17 2018-08-15 The Regents of the University of California Composition for treating acne
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
EP3035945B1 (en) * 2013-08-22 2018-03-14 Council of Scientific & Industrial Research A probiotic composition comprising the novel isolated bacterial strain of brevibacterium casei ap9
KR102379658B1 (ko) 2013-11-25 2022-03-28 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
HUE037476T2 (hu) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polipeptid és immunmodulálás
EP3065748B1 (en) 2014-12-23 2017-11-22 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
EP3294307A4 (en) 2015-05-14 2019-01-23 Crestovo Holdings Llc COMPOSITIONS FOR TRANSPLANTATION OF FECAL FLORA AND METHODS OF PREPARATION AND USE THEREOF, AND DEVICES FOR THEIR ADMINISTRATION
CN108243608A (zh) 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
PL3240554T3 (pl) 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis i wexlerae do stosowania w leczeniu chorób zapalnych i autoimmunologicznych
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS63089B1 (sr) 2015-06-15 2022-04-29 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EP3307288B1 (en) 2015-06-15 2019-07-24 4D Pharma Research Limited Compositions comprising bacterial strains
EP3313206A1 (en) * 2015-06-23 2018-05-02 Nestec S.A. Nutritional compositions and infant formulas containing oligofructose for reducing the load of pathogenic bacteria in the guts of infants and young children
CA3003908A1 (en) * 2015-11-03 2017-05-11 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
MA41013B1 (fr) 2015-11-20 2018-07-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3380108B1 (en) * 2015-11-24 2022-11-16 Seres Therapeutics, Inc. Designed bacterial compositions
AU2016361583B2 (en) * 2015-11-25 2021-05-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
CN106974940B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
LT3411052T (lt) * 2016-02-04 2021-01-11 Universiteit Gent Mikrobinių bendrijų naudojimas žmogaus ir gyvūno sveikatos pagerinimui
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
EP3423093A4 (en) 2016-03-04 2019-11-13 The Regents of The University of California MICROBIAL CONSORTIUM AND USES THEREOF
US11786562B2 (en) 2016-04-19 2023-10-17 Genome Research Limited Bacteriotherapy
KR20190017751A (ko) 2016-04-21 2019-02-20 네이키드 바이옴, 인크. 피부 장애의 치료를 위한 조성물 및 방법
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
DK3468573T3 (da) * 2016-06-14 2023-10-16 Vedanta Biosciences Inc Behandling af clostridium difficile infektion
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
RU2761873C2 (ru) * 2016-12-23 2021-12-13 Кэйо Юниверсити Композиции и способы для индукции cd8+ t-клеток
CN107058490B (zh) * 2017-01-12 2018-03-06 杨俊杰 肠道及口腔菌群多样性及差异性的分析方法
EP3606325A4 (en) 2017-04-03 2021-01-20 Gusto Global, LLC RATIONAL DESIGN OF BIOTHERAPEUTICS BASED ON MICROBES
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
WO2018195467A1 (en) 2017-04-21 2018-10-25 Memorial Sloan-Kettering Cancer Center Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof
EP3624818A4 (en) * 2017-05-19 2021-04-14 Memorial Sloan-Kettering Cancer Center METHODS AND COMPOSITIONS FOR REDUCING INFECTION OR COLONIZATION BY LISTERIA MONOCYTOGENES
PT3630136T (pt) 2017-05-22 2021-06-11 4D Pharma Res Ltd Composições que compreendem estirpes bacterianas
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
HRP20220747T1 (hr) 2017-06-14 2022-10-14 4D Pharma Research Limited Pripravci koji sadrže bakterijske sojeve
MD3638271T2 (ro) 2017-06-14 2021-03-31 4D Pharma Res Ltd Compoziții cuprizând tulpini bacteriene
IT201700068009A1 (it) * 2017-06-19 2018-12-19 Probiotical Spa Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson
EP3661525A4 (en) * 2017-08-04 2020-07-22 Second Genome, Inc. ROSEBURIA HOMINIS, EUBACTERIUM ELIGENS AND COMBINATIONS THEREOF AS BIOTHERAPEUTICS
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
EP3677272B1 (en) * 2017-08-29 2022-11-16 BGI Shenzhen Application of alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
US10874680B2 (en) 2017-09-25 2020-12-29 Tata Chemicals Limited Method of increasing relative abundance of oscillospira
AR113371A1 (es) * 2017-10-18 2020-04-22 Ascus Biosciences Inc Aumento de la producción de aves de corral mediante la administración de un bioensamblaje sintético de microbios o cepas purificadas de los mismos
EP3703720A1 (en) * 2017-10-30 2020-09-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
KR20200094178A (ko) 2017-11-29 2020-08-06 액세스 비지니스 그룹 인터내셔날 엘엘씨 피부 마이크로바이옴의 변형을 위한 방법 및 국소 조성물
WO2019115759A1 (en) * 2017-12-14 2019-06-20 Københavns Universitet Bacterial compositions and the use thereof for the treatment or prevention of asthma or other wheezing disorders or allergy in a child
EP3749751A4 (en) * 2018-02-09 2022-02-23 Keio University COMPOSITIONS AND METHODS FOR INDUCING CD8+ T LYMPHOCYTES
US20210361721A1 (en) * 2018-03-28 2021-11-25 Seres Therapeutics, Inc. Treatment of a cancer by microbiome modulation
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
KR20210008393A (ko) 2018-05-11 2021-01-21 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
WO2019226035A1 (ko) * 2018-05-25 2019-11-28 주식회사 엠디헬스케어 Qpcr 분석을 통한 대장암 진단방법
CN112218646B (zh) * 2018-05-31 2024-06-11 深圳华大生命科学研究院 一种组合物及其应用
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN108815199B (zh) * 2018-08-03 2021-10-01 南华大学 鼠衣原体在制备抗溃疡性结肠炎药物中的应用
JP2022514145A (ja) 2018-09-27 2022-02-10 フィンチ セラピューティクス ホールディングス エルエルシー てんかんおよび関連する障害を治療するための組成物および方法
US20220054560A1 (en) * 2018-10-15 2022-02-24 Pharmabiome Ag Consortia of living bacteria useful for treatment of colorectal cancer
WO2020097483A1 (en) * 2018-11-09 2020-05-14 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of dysbiosis
WO2020149719A2 (ko) * 2019-01-18 2020-07-23 주식회사 천랩 과민성대장증후군 특이적 미생물 바이오마커와 이를 이용하여 과민성대장증후군의 위험도를 예측하는 방법
US11969446B2 (en) * 2019-08-28 2024-04-30 Xbiome Inc. Compositions comprising bacterial species and methods related thereto
CN112438995A (zh) 2019-09-04 2021-03-05 台达电子工业股份有限公司 抑制具万古霉素抗药性肠球菌的益生菌及其组合与其用途
CA3153884A1 (en) 2019-10-07 2021-04-15 Nikole KIMES Therapeutic pharmaceutical compositions
EP3808358A1 (en) * 2019-10-17 2021-04-21 University College Cork-National University of Ireland, Cork Microbial compositions, strains and methods
WO2021146639A1 (en) * 2020-01-17 2021-07-22 Second Genome, Inc. Methods and compositions for treating colorectal cancer
WO2021167609A1 (en) * 2020-02-18 2021-08-26 Xia Xin Rui Method for treating and preventing coronavirus (covid-19) infection by direct pulmonary administration of a selected microorganism
RU2743696C1 (ru) * 2020-03-03 2021-02-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ производства капсулированной формы антимикробного препарата для терапии заболеваний желудочно-кишечного тракта
TW202203950A (zh) * 2020-03-30 2022-02-01 香港商香港微生物菌群創新中心有限公司 微生物在調節體重和膽固醇水準中的用途
CN111440884B (zh) * 2020-04-22 2021-03-16 中国医学科学院北京协和医院 源于肠道的诊断肌少症的菌群及其用途
KR102177180B1 (ko) * 2020-05-13 2020-11-10 순천대학교 산학협력단 신규 트레포네마 파지데니스 균주 및 이의 분리 방법
KR102177181B1 (ko) * 2020-05-14 2020-11-10 순천대학교 산학협력단 트레포네마 파지데니스 균주의 배양 조성물 및 이의 용도
CA3178618A1 (en) 2020-05-28 2021-12-02 David S. Harburger Airway medicaments
JP2023537608A (ja) 2020-08-14 2023-09-04 プロラクタ バイオサイエンス，インコーポレイテッド 細菌療法で使用するためのヒトミルクオリゴ糖組成物
CN111893077A (zh) * 2020-08-24 2020-11-06 河南金百合生物科技股份有限公司 一种丁酸梭菌的规模化生产方法
EP4210504A1 (en) * 2020-09-11 2023-07-19 MarvelBiome, Inc. Methods and uses of microbiome compositions
JP2023545458A (ja) * 2020-10-14 2023-10-30 ダームビオント インコーポレイテッド 皮膚の健康状態の改善、ならびに、真菌および他の病原性マイクローブに関連する疾患、障害および疾病の処置および予防のための組成物および方法
CN112322557A (zh) * 2020-12-07 2021-02-05 中诚国联（河南）生物科技有限公司 一种多功能复合微生物菌剂及其制备方法和应用
WO2022125785A1 (en) * 2020-12-10 2022-06-16 Boost Biomes, Inc. Use of selectable or detectable markers to identify interactions within a microbial community
CN113549671B (zh) * 2021-07-21 2023-09-08 连云港市第一人民医院 一种诊断维持性血液透析患者肌少症的肠道菌群
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
EP4386091A1 (en) * 2022-12-14 2024-06-19 The BioArte Limited A method for taxonomic classification up to species level of bacteria
CN116067612B (zh) * 2023-04-06 2023-06-23 中国航空工业集团公司沈阳空气动力研究所 利用升华法实现大型超声速风洞流动转捩位置观测的方法
CN117070416B (zh) * 2023-08-28 2024-02-23 中国科学技术大学 一株可缓解神经性贪食症的普拉梭菌及其应用
CN117286078B (zh) * 2023-11-21 2024-02-02 四川厌氧生物科技有限责任公司 一种改善胃肠道健康的植物乳植杆菌及其应用
CN117797176B (zh) * 2024-03-01 2024-07-02 南京大学 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009864A (en) 1958-09-18 1961-11-21 Union Carbide Corp Process control
US3228838A (en) 1959-04-23 1966-01-11 Union Carbide Corp Preservation of biological substances
US3009861A (en) 1961-01-13 1961-11-21 Alderton Gordon Isolation of bacterial spores
US3608030A (en) 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US4077227A (en) 1976-11-12 1978-03-07 Regents Of The University Of Minnesota Method of freezing liquid material in which agglomeration is inhibited
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
FI59925C (fi) 1980-01-11 1981-11-10 Esko Viljo Nurmi Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae
US4655047A (en) 1985-03-25 1987-04-07 I.Q.F. Inc. Process for freezing or chilling
JPS61252212A (ja) 1985-04-12 1986-11-10 Mitsubishi Petrochem Co Ltd 高吸水性ポリマ−の製造方法
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
WO1989003219A1 (en) 1987-10-12 1989-04-20 Borody Thomas J Improved method for treatment of gastrointestinal disorders
US5045446A (en) 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
GB2233343B (en) 1989-06-30 1993-07-07 Farmos Oy A bacterial preparation for use in poultry
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5436002A (en) 1991-01-29 1995-07-25 Mycogen Corporation Bacillus thuringiensisisolate PS201T6 toxin
RU2035186C1 (ru) 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
WO1997008598A1 (de) 1995-08-25 1997-03-06 Gff Technopark Verfahren zur simultanen, digitalen phasenempfindlichen detektion von zeitaufgelösten, quasi-gleichzeitig erfassten datenarrays eines periodisch stimulierten systems
CA2232001C (en) 1995-09-15 2002-12-10 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
AUPO430496A0 (en) 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
US5965128A (en) 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6589771B1 (en) 1999-10-28 2003-07-08 Immunom Technologies, Inc. Methods for arousing dormant bacteria
US20030118547A1 (en) 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
AU2001233529A1 (en) 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2100402A (en) 2000-11-30 2002-06-11 Bio Balance Corp Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
CN1678735A (zh) 2001-05-04 2005-10-05 佛罗里达大学研究基金会有限公司 来源于细菌的丙酮酸脱羧酶(pdc)基因的克隆和测序及其用途
ITMI20011632A1 (it) 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
NZ542866A (en) 2003-04-23 2009-07-31 Medarex Inc Compositions and methods for the therapy of inflammatory bowel disease
EP1473370A3 (en) 2003-04-24 2005-03-09 BioMerieux, Inc. Genus, group, species and/or strain specific 16S rDNA Sequences
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
RU2006108554A (ru) 2003-08-18 2007-09-27 Дзе Байо Бэлэнс Корпорейшн (Us) Устойчивая жидкая пробиотическая композиция, ее получение и применения
US20050048515A1 (en) 2003-08-29 2005-03-03 Garner Bryan E. Methods for detecting and quantifying specific probiotic microorganisms in animal feed
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
BRPI0507410B1 (pt) 2004-02-03 2020-11-03 Prevtec Microbia Inc uso de cepa f4+ não patogênica da escherichia coli e métodos que a utilizam para promover e homogeneizar crescimento de animais
US7632520B2 (en) 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
EP1815016B1 (en) 2004-11-01 2012-06-27 George Mason University Compositions and methods for diagnosing colon disorders
AU2005302390A1 (en) 2004-11-01 2006-05-11 Strategic Diagnostics, Inc. Bacteriophages as selective agents
US20060188523A1 (en) 2005-01-10 2006-08-24 Zhiheng Pei Methods for diagnosing and treating chronic tonsillitis
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2277524B1 (en) 2005-09-28 2015-11-11 Nordisk Rebalance A/S Treatment of IBS using both probiotic bacteria and fermented cereal as treatment effectors
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
JP2009537138A (ja) 2006-05-18 2009-10-29 バイオバランス エルエルシー 細菌株、この細菌株を含む組成物およびそのプロバイオティック使用
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
US8147482B2 (en) 2006-06-20 2012-04-03 MEDIMETRICS Personalized Drug Delivery B.V. Electronic capsule for treating gastrointestinal disease
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EE05459B1 (et) 2006-12-08 2011-08-15 Tartu �likool Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
US20100172874A1 (en) 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
WO2009036121A1 (en) 2007-09-12 2009-03-19 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
US8236508B2 (en) 2008-01-29 2012-08-07 Drexel University Detecting and measuring live pathogens utilizing a mass detection device
US8021654B2 (en) 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains
KR20100134080A (ko) 2008-04-01 2010-12-22 메타메트릭스 클리니칼 레보러토리 위장의 미생물상을 모니터링하기 위한 공정과 방법
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
EP2313773A1 (en) 2008-07-15 2011-04-27 Metanomics Health GmbH Means and methods diagnosing gastric bypass and conditions related thereto
JPWO2010024251A1 (ja) 2008-08-26 2012-01-26 オリンパス株式会社 糞便試料の調製方法、糞便試料調製用溶液、及び採便用キット
WO2010030997A1 (en) 2008-09-12 2010-03-18 The Washington University Regulating intestinal microbiota dependent signaling as a means to modulate body fat and/or weight loss
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
EP2367839A4 (en) 2008-11-03 2012-07-04 Univ Tufts METHODS AND COMPOSITIONS FOR PREVENTING GERMINATION AND EXCROIDANCE OF C. DIFFICILE SPORES
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
IT1393931B1 (it) 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composizione di spore di batteri non patogeni
US20120128633A1 (en) 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
BRPI1009920A2 (pt) 2009-05-01 2016-03-15 Micropharma Ltd composições bacterianas para profilaxina e tratamento de doença degenerativa.
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
CA2766312C (en) 2009-06-26 2020-04-14 Gary L. Andersen Methods and systems for phylogenetic analysis
US20120264637A1 (en) 2009-06-26 2012-10-18 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
PL2467031T3 (pl) 2009-08-18 2015-03-31 Nestec Sa Odżywcza kompozycja zawierająca szczepy lactococcus i zmniejszająca objawy alergiczne, zwłaszcza dla małych dzieci i dzieci
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
US20120149584A1 (en) 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
PL2480255T3 (pl) 2009-09-23 2018-07-31 Thomas Julius Borody Terapia przewlekłych zakażeń jelitowych
US20120238468A1 (en) 2009-10-05 2012-09-20 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20120276149A1 (en) 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
JP6006117B2 (ja) 2009-11-12 2016-10-12 ネステク ソシエテ アノニム 腸内微生物叢バランス及び健康を促進するための栄養組成物
US9138441B2 (en) 2009-12-31 2015-09-22 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US9492487B2 (en) 2010-02-01 2016-11-15 Matthew Ryan Garner Microbial product containing multiple microorganisms
SI3564357T1 (sl) 2010-02-01 2022-09-30 Rebiotix, Inc. Bakterioterapija Clostridium Difficile colitisa
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
WO2011107482A2 (en) 2010-03-01 2011-09-09 Institut National De La Recherche Agronomique Method of diagnostic of obesity
EP2542690A2 (en) 2010-03-01 2013-01-09 Institut National de la Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011113801A1 (en) 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
US9005601B2 (en) 2010-07-16 2015-04-14 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
FI20105825A (fi) * 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
AU2011286165B2 (en) 2010-08-04 2016-10-20 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
AU2011299285B2 (en) 2010-09-10 2017-01-05 Ntcd, Llc Environmental Clostridial bacteriotherapy and related formulations and methods of manufacture and use
EP2646567A4 (en) 2010-10-04 2014-03-26 British Columbia Cancer Agency DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE TO DIAGNOSE GASTROINTESTINAL CANCER
WO2012064981A2 (en) 2010-11-10 2012-05-18 National Jewish Health Methods to test allergic conditions
US20120064592A1 (en) 2011-01-26 2012-03-15 Qteros, Inc. Biocatalysts synthesizing deregulated cellulases
PL2672980T3 (pl) 2011-02-09 2018-05-30 Lavivo Ab Synbiotyczne kompozycje dla odnowienia i odtworzenia flory bakteryjnej jelita
AR085409A1 (es) 2011-02-25 2013-10-02 Tricorder Diagnostics Llc Firmas microbianas como indicadores de exposicon a radiacion
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120276056A1 (en) 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
US20140179726A1 (en) 2011-05-19 2014-06-26 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
WO2013016636A1 (en) 2011-07-27 2013-01-31 Max International, Llc Compositions comprising sugar-cysteine products
WO2013019896A1 (en) 2011-08-01 2013-02-07 Symbiotix Biotherapies, Inc. Platform for identifying and/or characterizing immunomodulatory agents
KR101982491B1 (ko) 2011-08-30 2019-05-27 아카데미쉬 메디쉬 센트륨 인슐린 저항 예방 및/또는 치료 방법
CA2848762C (en) 2011-09-14 2021-07-27 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
US20130115232A1 (en) 2011-10-03 2013-05-09 Fred Hutchinson Cancer Research Center Methods for detecting graft-versus-host disease
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EA201490512A1 (ru) 2011-10-11 2014-09-30 Ачим Байотерапьютикс Аб Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
GB201201766D0 (en) 2012-02-01 2012-03-14 Imp Innovations Ltd Method
US20150125883A1 (en) 2012-04-30 2015-05-07 Washington University Method of isolating and characterizing microorganisms that are targets of host immune responses
WO2013171515A1 (en) 2012-05-18 2013-11-21 Genome Research Limited Methods and groups
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP6257600B2 (ja) 2012-05-25 2018-01-10 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病の治療方法
EP2684469A1 (en) 2012-07-13 2014-01-15 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth
SG10201704035TA (en) 2012-11-23 2017-06-29 Seres Therapeutics Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
JP2016520305A (ja) 2013-05-03 2016-07-14 ネステク ソシエテ アノニム 消化管微生物叢中のラクノスピラ科細菌及び体重との関連性
WO2015018308A1 (en) 2013-08-06 2015-02-12 BGI Shenzhen Co.,Limited Biomarkers for colorectal cancer
KR102379658B1 (ko) 2013-11-25 2022-03-28 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
EP3380108B1 (en) 2015-11-24 2022-11-16 Seres Therapeutics, Inc. Designed bacterial compositions
EP4368254A2 (en) 2016-03-14 2024-05-15 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
EP3703720A1 (en) 2017-10-30 2020-09-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance

Also Published As

Publication number Publication date
CN116370507A (zh) 2023-07-04
CA3203756A1 (en) 2015-05-28
JP2021059545A (ja) 2021-04-15
WO2015077794A4 (en) 2015-07-30
KR102515850B1 (ko) 2023-03-30
MX2019009132A (es) 2019-10-09
CA2931317C (en) 2023-08-22
US20170151291A1 (en) 2017-06-01
RU2016125316A (ru) 2018-01-09
RU2722482C2 (ru) 2020-06-01
JP6833514B2 (ja) 2021-02-24
JP2024038027A (ja) 2024-03-19
US20200345792A1 (en) 2020-11-05
MX2016006708A (es) 2016-10-26
JP2016537434A (ja) 2016-12-01
AU2014352643A1 (en) 2016-06-30
JP7473285B2 (ja) 2024-04-23
KR102379658B1 (ko) 2022-03-28
US11266699B2 (en) 2022-03-08
CN105979952B (zh) 2022-04-08
US11918612B2 (en) 2024-03-05
AU2021200287A1 (en) 2021-03-18
KR102611070B1 (ko) 2023-12-07
US10258655B2 (en) 2019-04-16
US20220257674A1 (en) 2022-08-18
WO2015077794A1 (en) 2015-05-28
AU2023219938A1 (en) 2023-10-26
AU2021200287B2 (en) 2023-05-25
KR20160095006A (ko) 2016-08-10
BR112016011830A2 (pt) 2017-09-26
CN105979952A (zh) 2016-09-28
EP3074027A1 (en) 2016-10-05
KR20220042246A (ko) 2022-04-04
CA2931317A1 (en) 2015-05-28
KR20230047502A (ko) 2023-04-07

Similar Documents

Publication Publication Date Title
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
PH12016501512A1 (en) Treatment for resistant acne
IN2015DN01156A (es)
WO2014145958A3 (en) Network-based microbial compositions and methods
MX2019014045A (es) Composiciones y metodos.
GB201106750D0 (en) Novel compounds
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
MX2015010125A (es) Derivados de piridazinona-amidas.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MY158992A (en) Forms of rifaximin and uses thereof
PH12014501991B1 (en) Phenicol antibacterials
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX366368B (es) Metodos para el cuidado oral prebiotico usando un sacarido.
MX365403B (es) Peptidos y metodos para usarlos.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
SG10201900541QA (en) Derivatives of xanthone compounds
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
PH12014501239A1 (en) Thymol and totarol antibacterial composition
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
IN2013MU03216A (es)

Legal Events

Date Code Title Description
FG Grant or registration